Monjuvi + Rituximab & Lenalidomide: The First and Only CD19- and CD20-targeted Immunotherapy Combination for 2L+ Follicular Lymphoma Patients

Event Date:

Mar 04, 2026

Credit Type:

--

Credits:

--